- NEWS FEATURE
Cancer drugs are closing in on some of the deadliest mutations

Chemists have struggled to design drugs that interact with the KRAS protein’s relatively smooth surface. Credit: Alamy
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 610, 620-622 (2022)
doi: https://doi.org/10.1038/d41586-022-03392-2
References
Skoulidis, F. et al. N. Engl. J. Med. 384, 2371–2381 (2021).
Fakih, M. G. et al. Lancet Oncol. 23, 115–124 (2022).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).
Wang, X. et al. J. Med. Chem. 65, 3123–3133 (2022).
Canon, J. et al. Nature 575, 217–223 (2019).
Zhang, Z. et al. Cancer Cell 40, 1060–1069 (2022).